Literature DB >> 17130965

[Molecular characterization of ABO*O alleles at the ABO group locus in three chilean populations].

Elena Llop R1, Hugo Henríquez B, Mauricio Moraga V, Mario Castro D, Francisco Rothhammer E.   

Abstract

BACKGROUND: Among the allelic variants of blood groups, the molecular characterization of ABO blood group has clinical and anthropological importance. AIM: To perform a characterization of the molecular variants of the allele ABO*O of the ABO blood group.
MATERIAL AND METHODS: Eighty four subjects of Aymara origin, living in Northern Chile, 75 individuals of Huilliche origin, living in Southern Chile and 82 subjects living in Santiago (Central Chile), were studied. All individuals were of group O, homozygotes for G261- deletion, that defines O1 alleles. Mutations G188A, G261-, G542A, T646A and C771T, described for alleles O1, O1variant and G542A were determined by PCR-RFLP (polymerase chain reaction-restriction fragment lenght polymorphism).
RESULTS: Allele O1variant has frequencies of 0.65, 0.81 and 0.6 in Aymara, Huilliche and Santiago subjects, respectively. The figures for allele O1 are 0.35, 0.19 and 0.4, respectively and those for the allele with G542A mutation are 0.119, 0.113 and 0.079, respectively.
CONCLUSIONS: These results are concordant with the reported higher frequency of allele O1variant in South American aboriginal populations. The frequencies of G542A allele in these Chilean individuals are lower than those described for Amazon aborigines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17130965     DOI: 10.4067/s0034-98872006000700005

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  1 in total

1.  Transcranial Doppler in a Hispanic-Mestizo population with neurological diseases: a study of sonographic window and its determinants.

Authors:  Alejandro M Brunser; Claudio Silva; Daniel Cárcamo; Paula Muñoz; Arnold Hoppe; Verónica V Olavarría; Violeta Díaz; Juan Abarca
Journal:  Brain Behav       Date:  2012-05       Impact factor: 2.708

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.